Page 177 - CW E-Magazine (24-9-2024)

Special Report

III are very promising, and GlobalData ting obesity and related metabolic indi- Type 2 diabetes; and
expects them to reach the-billion-dollar cations with various mechanisms of  CT-868, a once-daily subcutaneous

sales mark within a couple of years action. Some key pipeline contenders injectable, in Phase II, for treating
from their launch.” in both early and late-stage develop- Type 1 diabetes patients with over-
ment noted by analysts include: weight or obesity.
The rise of Lilly’s and Novo Nor-  Novo Nordisk’s monlunabant, amy-
disk’s GLP-1 drugs has given new life cretin, and INV-202; These drug candidates are incretins,
to the market for obesity drugs overall.  Lilly’s eloralintide, retatrutide, and which are gut hormones that are secreted

Novo Nordisk’s Wegovy and Eli Lilly’s orforglipron as well as bimagrumab after food intake and play a role in
Target Your Market More Effectively
Mounjaro generated $9.7-bn globally (acquired through Lilly’s $1.9-bn modulating blood glucose by stimulating
in 2023, which represented a 239% acquisition of Versanis Bio in insulin secretion and suppressing
increase from the total revenue generated 2023); IndiaChemTrade
appetite. Roche says the incretin-based
ChemImpex
from all obesity drugs in 2022, according  Pfi zer’s danuglipron; portfolio could also be expanded to

to information from GlobalData. Start-  Boehringer Ingelheim’s and Zea- other indications where incretins play
For subscribers only
Free for subscribers of Chemical Weekly
ing in 2024, signifi cant increases in land Pharma’s survodutide; and a role, including cardiovascular, retinal,
ChemImpex, the trade database, tracks, on a daily
IndiaChemTrade provides consolidated trade statistics
the number of launches of new obesity  Amgen’s MariTide (maridebart and neurodegenerative diseases.

basis, exports and imports of chemicals and related
drugs are expected per year, culminat- cafraglutide). of India. The information provided here is based on the
products through the major ports in India — a vital
In November 2023, AstraZeneca
ing in a peak of four launches in both annual trade data published by the Directorate General
source of commercial intelligence. Find out on-line
of Commercial Intelligence and Statistics, Government
2027 and 2028, according to estimates Interest in the obesity drug market formed a $2.0-bn pact ($185-mn up-
how international markets are moving; where your
of India. The database can be searched by: Chemical
by GlobalData. Novo Nordisk is look- is also engendering recent deal-making. front and $1.825-bn in potential mile-
Name/Harmonised
ing to cement its position as an obesity In January 2024, Roche acquired Car- Code to obtain the consolidated
competitors are exporting and at what price; where
stones) with Eccogene, a Shanghai,
trade (import or export) in that item; or by Country to
imports are coming from and how their prices are
front-runner, as it will account for six of mot Therapeutics, a Berkeley, California- China-based clinical-stage bio/pharma-
based bio/pharmaceutical company, ceutical company, for an exclusive
moving. Download all this data,
the 13 estimated launches. Its lead pipe- seamlessly, for a obtain the trade (import or export) in all chemicals and
line drug, CagriSema (semaglutide and in a deal worth up to $3.1-bn ($2.7-bn license for Ecogene’s ECC5004, cur-
small fee — online, anytime, with no hassles.
related products between India and that country
cagrilintide), is currently in Phase III at closing plus $400-mn in potential rently in Phase I, for treating obesity,
ChemXchange
development for obesity. This product milestone payments). The acquisition Type-2 diabetes, and other cardiometa-
is expected to launch in the US by the provides Roche with three clinical- bolic conditions.
Open to all registered users — no subscription required
end of 2025, and is forecast to generate stage assets with potential in treating
ChemXchange — the chemical exchange with a difference — is where you can identify your buyers and sup-
$7.4-bn in revenue by 2029, according obesity and diabetes. These include: Other bio/pharma companies with
plyers on-line, any time. This unique platform is free to all advertisers in the print version of Chemical Weekly.
to estimates from GlobalData.  CT-388, a once-weekly subcutane- key pipeline contenders in the obesity
ous injectable in Phase II, for treating drug market noted by analysts include:
For more information contact: 022-24044477. Fax: 022-24044450
Pipeline contenders obesity in patients with and without Regeneron Pharmaceuticals’ trevo-
Email: corporate@chemicalweekly.com or log on to chemicalweekly.com
In looking at the obesity drug mar- Type 2 diabetes; grumab; Altimmune’s pemvidutide;
ket specifi cally, Novo Nordisk, Lilly,  CT-996, a once-daily oral small- Innovent Biologics’ mazdutide; Viking

and other large bio/pharma companies molecule drug, in Phase I, for treating Therapeutics’ VK-2735; and Structure
are advancing drug candidates for trea- obesity in patients with and without Therapeutics’ GSBR-1290.
Missed a copy !!!
For Digital Edition of this month’s issue & all other past issues
Visit www.hpicindia.com
PDF copies available for download
Register Now
Contact: For Subscription : Mrs. Usha S. - usha@hpicindia.com
Mrs. Usha S. - usha@hpicindia.com
For Advertising : Mr. Vijay Raghavan - vijay@hpicindia.com
Chemical Weekly September 24, 2024 177
Contents Index to Advertisers Index to Products Advertised